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Abstract
Two sensitive reversed-phase high-performance liquid chromatographic fluorescence methods, with simple sample
handling at the site of the patient, are described for the determination of the lactone and lactone plus carboxylate forms of
9-aminocamptothecin (9AC). For 9AC lactone, the sample preparation was a liquid–liquid extraction with acetonitrile–n-
butyl chloride (1:4, v /v), whereas the sample preparation for 9AC total (lactone plus carboxylate) was a simple
deproteinization with 5% perchloric acid–methanol (1:1, v /v), which results in the conversion of the carboxylate into the
lactone form. The lower limits of quantitation were 50 pg/ml and 100 pg/ml for 9AC lactone and 9AC total, respectively.
The within-run precisions at four tested concentrations were #6.3% for 9AC lactone and #5.3% for 9AC total. The
between-run precisions were #8.9% and #5.6%, respectively. The assays were developed to enable pharmacological
analysis of 9AC in a bioavailability and oral phase I study in patients with solid tumors.  1997 Elsevier Science B.V.
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1. Introduction toxicity, including diarrhea and dose-limiting
myelosuppression precluded further clinical testing
20(S)-Camptothecin (CPT; NSC 94600; Fig. 1) is (reviewed in Ref. [3]). After the identification of
a cytotoxic plant alkaloid, that was first extracted DNA topoisomerase I as the molecular target of CPT
from the wood and bark of the oriental tree Cam- [4,5], interest in new structure development was
ptotheca acuminata, Decaisne (Nyssaceae) [1,2]. In accelerated, with various derivatives of CPT
spite of promising antitumor activity in vitro and in (semi)synthesized to enhance the aqueous solubility.
animal tumor models, severe and unpredictable Two compounds of this type, viz. topotecan and
irinotecan have shown impressive antitumor activity
and were recently registered for clinical use in
various countries, for treatment of ovarian and
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Netherlands. camptothecin (9AC; NSC 603071; Fig. 1) was
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Fig. 1. Chemical structures and pH-dependent interconversion of the lactone and carboxylate forms of 9AC (R5NH ) and CPT (R5H).2
recently also introduced into clinical trials because of 2. Experimental
its unprecedented antitumor activity against solid
tumor xenografts [7,8]. 2.1. Chemicals and reagents
Pharmacokinetic studies of the camptothecins,
including 9AC, are complicated by a chemical, pH- 9AC (Lot No. 93L07A, containing the base with a
dependent instability of the lactone ring (Fig. 1) [9], purity of 100%) and CPT (Lot No. 93K05A, con-
generating an open-ring carboxylate, which is over taining the base with a purity of 100%) were
1000-fold less active as an inhibitor of DNA obtained from Pharmacia (New Mexico, USA).
topoisomerase I [10]. The importance of this Methanol, acetonitrile (both HPLC-grade), dimethyl
nonenzymatic hydrolysis reaction of the lactone sulfoxide (DMSO) and n-butyl chloride (both ana-
moiety in the pharmacology and toxicology of 9AC lytical grade) were purchased from Rathburn (Walk-
is largely unknown. To address this question, de- erburn, UK). Perchloric acid (70–72%, v/v; ana-
velopment of analytical methodologies enabling the lytical grade) was obtained from Baker (Deventer,
quantitation of both forms are required. Various Netherlands). The water was filtered and deionized
authors recently described assays for the determi- with a Milli-Q-UF system (Milford, MA, USA) and
nation of 9AC lactone and/or total drug levels was used in all aqueous solutions. Drug-free human
(lactone plus carboxylate; 9AC total) applicable to plasma originated from healthy donors and was
plasma samples obtained from patients [11–13]. delivered by the Central Laboratory of the Blood
Major drawbacks of these procedures are the necessi- Transfusion Service (Amsterdam, Netherlands).
ty for immediate analysis by high-performance liquid
chromatography (HPLC), postcolumn acidification
and/or laborious solid-phase extraction techniques. 2.2. Stock solutions and standards
We now describe novel assays for the analysis of
9AC lactone and 9AC total in human plasma, which Separate stock solutions of 9AC and CPT were
only require a one-step solvent extraction for sample made by dissolving 10.0 mg of 9AC or CPT in 10.00
clean-up prior to reversed-phase HPLC with fluores- ml of DMSO. A volume of 5.00 ml of these
cence detection. The presented methods have been solutions was accurately transferred to 50 ml volu-
thoroughly validated in terms of accuracy and preci- metric flasks and diluted to the mark with DMSO,
sion, and are now successfully implemented in resulting in solutions containing 100 mg/ml of 9AC
studies on the pharmacology of 9AC in patients with or CPT, respectively. Working solutions of 9AC
solid tumors. lactone were prepared daily at 1, 2, 10, 20, 30 and 40
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ng/ml by serial dilution in a mixture of methanol– added. The sample was transferred to a low volume
water–perchloric acid (500:500:1, v /v /v) from the insert of glass, and a volume of 150 ml was injected
primary stock solution. Similarly, working solutions into the HPLC system.
of 9AC total were made in methanol–water (1:1,
v /v) at concentrations of 2, 4, 20, 100, 200 and 300
ng/ml. Spiked plasma samples used as calibrations 2.4. Sample preparation for total 9AC
standards were prepared daily by addition of 50 ml of
the working solutions to 950 ml of drug-free human A volume of 250 ml of 5% perchloric acid–
plasma, resulting in calibration standards of 50, 100, methanol (1:1, v /v) was added to 250 ml of human
500, 1000, 1500 and 2000 pg/ml for 9AC lactone plasma in a 1.5 ml polypropylene-microcentrifuge
and of 100, 200, 1000, 5000, 10 000, 15 000 pg/ml tube, followed by vortex-mixing for 10 min. Sub-
for 9AC total. sequently, the sample was centrifuged for 5 min at
Four pools of quality control (QC) samples were 24 000 g at ambient temperature. The clear superna-
prepared in human plasma in the concentrations of tant was transferred to a low volume insert of glass
250, 900, 1600 and 150 000 pg/ml for 9AC lactone and 200 ml were injected into the HPLC system.
and of 500, 7500, 12 500 and 250 000 pg/ml for
9AC total. The QC samples containing the highest
concentration were used as diluted control and/or for 2.5. Chromatographic system
low volume injection. To minimize differences in the
composition between clinical and QC samples, also The HPLC system consisted of a constaMetric
the carboxylate form of 9AC was added to the QC 3200 pump from LDC Analytical, a subsidiary of
samples of 9AC lactone. The 9AC carboxylate was Thermo Instruments Systems (Riviera Beach, USA).
spiked at the same concentrations as 9AC lactone The samples were injected by a Waters 717plus
and was prepared by adding 9AC in methanol–water autosampler (division of Millipore, Milford, MA,
(1:1, v /v) to plasma, followed by incubation at 378C USA). A fluoriMonitor 4100 fluorescence detector
for 20 h. from LDC Analytical was used for the detection.
Chromatographic separations were achieved on an
Inertsil ODS-80A column (15034.6 mm I.D., 5 mm
2.3. Sample preparation for the lactone form of particle size) from GL Science (Tokyo, Japan),
9AC protected by a Lichrospher 100 RP-18 endcapped
guard column (434 mm I.D., 5 mm particle size)
To 1.00 ml of human plasma a volume of 100 ml obtained from Merck (Darmstadt, Germany).
of 2.5 ng/ml of CPT in methanol–water–perchloric For the assay of the lactone form of 9AC in
acid (500:500:1, v /v /v) and 0.8 g of NaCl were plasma, the mobile phase was a mixture of metha-
added in a glass tube supplied with PTFE-covered nol–water (40:60, v /v). The pH was adjusted to 2.20
screw cap. For the extraction, 7.5 ml of acetonitrile– by addition of perchloric acid. The mobile phase for
n-butyl chloride (1:4, v /v) was added and the sample the assay of 9AC total in plasma was composed of
was vortex-mixed for 5 min, which resulted in the methanol–water (32.5:67.5, v /v), with the pH ad-
formation of a gel. Subsequently, the sample was justed to 2.10 using perchloric acid. The mobile
centrifuged for 2 min at 4000 g at ambient tempera- phases were degassed by ultrasonication and were
ture. The sample was shaken once to break the gel delivered at a flow-rate set at 1.00 ml /min for both
and centrifuged for 5 min at 4000 g. The supernatant assays. The column was maintained at 408C, also for
was collected in a glass tube containing 50 ml of both assays, using a model SpH99 column oven
DMSO and evaporated at 508C under a gentle stream (Spark Holland, Meppel, Netherlands), and the
of nitrogen, until a residue of approximately 50 ml eluents were monitored at an excitation wavelength
was left over. To the residue 50 ml of methanol and of 370 nm and an emission wavelength of 450 nm,
150 ml of perchloric acid–water (1:500, v /v) was with a bandwidth of 40 nm.
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2.6. Calibration The stability of 9AC total was tested by incubation
of the four QC samples at 378C for 20 h and during
Acquisition and integration of chromatographic three freeze–thaw cycles. At the freeze–thaw cycles
data was performed with the Chrom-Card data the QC samples were put at room temperature for 1 h
analysis system (Fisons, Milan, Italy) running on an before freezing again. The stability of 9AC lactone
ICW workstation. Calibration curves were made by was only tested during three quick freeze–thaw
linear regression analysis of peak heights versus cycles. The samples were thawed quickly in cold
1/concentration using the software package Lotus water and restored at 2808C within 5 to 10 min. The
2.4 (Lotus Development Corporations, New York, long term stability of 9AC total and 9AC lactone at
NY, USA). 2808C was also tested at the concentrations of the
QC samples over a four-month period.
2.7. Validation The following potentially co-administered drugs
were tested for interference with the analytical
For the validation of the assays of 9AC lactone methods: paracetamol at a concentration of 0.50
and 9AC total in plasma, the six-points calibration mg/ml; alizapride, codeine, domperidon, morphine
curves were processed in duplicate and analyzed on and ranitidine at a concentration of 0.10 mg/ml; and
four occasions with the lower limit of quantitation dexamethasone and metoclopramide at concentra-
(LLQ) and the QC samples in quintuplicate. For the tions of 0.05 and 0.01 mg/ml, respectively.
determination of the LLQ, plasma samples of five
independent individuals were taken and spiked to 2.8. Human experiments
contain 50 pg/ml for 9AC lactone and 100 pg/ml for
9AC total. For the concentration accepted as the To demonstrate the applicability of the analytical
LLQ, the percent deviation of at least 80% of the methods, blood samples from a patient were col-
samples assayed should be #20%. The mean within- lected at 0, 20 and 40 min, and at 1, 1.5, 2, 3, 5, 7.5,
run and between-run precision (expressed as the 11, 24, 28, 31, 35, 48, 52 and 55 h after oral
coefficient of variation (%C.V.) for each concen- administration of 2.5 mg of 9AC. Immediately after
tration, excluding the LLQ, should be #15% and sampling, the blood was centrifuged, at the site of
should be #20% for the LLQ. The mean accuracy the patient, for 5 min at 3000 g at 48C. The plasma
(%) for each concentration, including the LLQ, was collected and directly placed on dry-ice at
should be within 85–115% of the nominal values. 2208C. Within a few hours the samples were stored
The absolute recoveries were calculated on the at 2808C.
basis of the concentrations of the calibration curves.
For 9AC lactone the peak heights of processed
plasma samples were compared with the peak 3. Results and discussion
heights of two samples with a concentration equiva-
lent to 1000 pg/ml 9AC and 250 pg/ml CPT in Calibration curves of the lactone and total (lactone
plasma extracts with 100% recovery. For this pur- plus carboxylate forms) of 9AC in human plasma
pose, 50 ml of 20 ng/ml of 9AC and 100 ml of 2.5 were linear in the range of 50 to 2000 pg/ml and 100
ng/ml of CPT in methanol–water–perchloric acid to 15 000 pg/ml, respectively. The regression corre-
(500:500:1, v /v /v) were evaporated in a tube con- lation coefficients were $0.992 for 9AC lactone and
taining 50 ml of DMSO, and were dissolved as $0.997 for 9AC total, by using weighted (1 /con-
plasma extracts. For 9AC total, the peak heights of centration) linear least-squares regression analysis to
processed plasma samples were compared with the prevent domination of the highest concentrations.
peak heights of two samples with a concentration Intercept values of the standard curves for both 9AC
equal to 5000 pg/ml of 9AC in plasma extracts with lactone and 9AC total were not significantly different
100% recovery; 25 ml of 100 ng/ml of 9AC in from zero by Student’s t-test (P.0.05). The re-
methanol–water (1:1, v /v) was added to 975 ml tention times of 9AC and CPT in the assay of the
blank plasma extract. lactone form were 7.5 and 22 min (Fig. 2), while the
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retention time of 9AC in the assay of 9AC total was
12.5 min (Fig. 3), with overall chromatographic run
times of 30 and 20 min, respectively. The selectivity
for the analytes is shown by the sharp resolution of
the peaks and no significant interfering peaks for
both assays in blank plasma samples from five
independent donors. All the tested potentially co-
administered drugs did not give interfering peaks for
9AC and CPT in the assay for 9AC lactone, and for
9AC in the assay for the 9AC total.
The LLQ for 9AC in the assays for the lactone and
total form were 50 and 100 pg/ml, respectively. The
lower value of the LLQ for the determination of the
lactone was a consequence of concentration of theFig. 2. Chromatograms of a blank human plasma sample con-
sample as compared to dilution of the sample in thetaining 250 pg/ml of CPT, used as internal standard (A), and a
assay for 9AC total. The extraction recoveries ofhuman plasma sample containing 171 pg/ml of 9AC and 250
pg/ml of CPT (B) in the assay for 9AC lactone. Peaks labeled I 9AC and CPT in the assay for 9AC lactone were
and II correspond to 9AC and CPT, respectively. 78.267.98% and 92.467.96%, and the recovery for
9AC in the total assay was found to be 89.666.87%.
The extraction procedure was shown to be highly
selective for 9-AC lactone, since less than 0.1% of
the 9-AC caboxylate form present in the samples was
extracted concomitantly. In both assays, extraction
recoveries were independent of the spiked concen-
tration. The within-run precisions of the LLQ sam-
ples of 9AC lactone and 9AC total were #4.2% and
#10.2%, respectively. The range of accuracy for
9AC lactone was 95.6% to 112.0%. For 9AC total,
the accuracy ranged from 95.2% to 107.6%. The
average accuracy for QC samples at the four tested
concentrations in both assays showed values ranging
within 10% of the nominal values (Tables 1 and 2).
The average within-run and between-run precisions
Fig. 3. Chromatograms of a blank human plasma sample (A), and for 9AC lactone and 9AC total in human plasma
a 10-fold diluted human plasma sample containing 89 264 pg/ml varied upto 8.9% and 5.6%, respectively (Tables 1
of 9AC (B) in the assay for 9AC total. The peak labeled I
and 2).
corresponds to 9AC. 9AC total was found to be stable for 20 h at 378C,
Table 1
The mean accuracy, the mean within-run precision and the between-run precision of the QC samples (n55) in human plasma of 9AC
lactone
QC sample Accuracy Precision (%)
(pg/ml) (mean) (%)
Within-run (mean) Between-run
250 101.6 1.0 3.5
900 91.5 2.4 2.9
1600 90.3 1.7 5.2
150 000 98.9 4.1 8.9
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Table 2
The mean accuracy, the mean within-run precision and the between-run precision of the QC samples (n55) in human plasma of 9AC total
QC sample Accuracy Precision (%)
(pg/ml) (mean) (%)
Within-run (mean) Between-run
500 102.6 2.5 3.6
7500 103.1 1.4 5.6
12 500 103.5 1.5 5.0
250 000 98.4 2.4 2.2
and during three freeze–thaw cycles. However, 9AC re-converting the carboxylate into the corresponding
lactone, enabled determination of 9AC total. Thelactone was not stable during three quick freeze–
plasma concentration–time curves of 9AC lactonethaw cycles; there was a loss of the amount of 9AC
and 9AC total forms of a patient treated orally withlactone of approximately 10% in comparison with
2.7 mg of 9AC, are given in Fig. 4. The data indicatethe mean of a set of QC samples analyzed at the
that the LLQs of 50 and 100 pg/ml for 9AC lactonesame time. This instability necessitates quick freez-
and 9AC total, respectively, are sufficient for moni-ing of the samples after blood sampling in order to
toring drug-plasma levels in samples obtained fromstabilize the ratio between 9AC lactone and 9AC
patients treated at low oral doses.carboxylate. 9AC total and lactone forms were stable
In conclusion, two sensitive, selective, accuratefor at least four months when stored at 2808C.
and reproducible isocratic reversed-phase HPLCProcessed plasma samples were also found to be
methods have been developed for the analysis ofstable at ambient temperature upon standing in the
9AC lactone and 9AC total in human plasma. Theautosampler tray for at least 20 h.
sample pretreatment procedures are based on singlePlasma collected from a patient prior to the drug
solvent extractions, thereby eliminating the need ofadministration did not reveal the presence of interfer-
laborious solid-phase extraction techniques [12,13].ing endogenous peaks. Concentrations of 9AC lac-
Compared to previously described assays for 9AC,tone could be readily estimated from protein-free
our new methods provide equivalent to superiorextracts, whereas acidification of plasma samples,
sensitivity with LLQs of 50 pg/ml for 9AC lactone
and 100 pg/ml for 9AC total (lactone plus car-
boxylate). The methodologies described permit the
analysis of patient samples, and will be implemented
in future investigations on the clinical pharmacology
of 9AC administered at low (oral) doses.
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